Tests for biomarkers that can identify preclinical Alzheimer’s disease are raising hopes for earlier treatments but are also raising new concerns about how the information will be used by insurers and employers.
NeuroEthics Program: Matters of the Mind
Cleveland Clinic’s NeuroEthics Program helps clinicians and researchers explore ethical issues and offers guidance to patients and families struggling with decisions on diagnosis and care.